
Sign up to save your podcasts
Or


In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today’s CDMO funding trends are shaping the next phase of growth and specialization across the contract research and manufacturing ecosystem.
Brian shares his perspective on:
By Pharma Manufacturing5
66 ratings
In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today’s CDMO funding trends are shaping the next phase of growth and specialization across the contract research and manufacturing ecosystem.
Brian shares his perspective on:

7,679 Listeners

10,752 Listeners

28 Listeners

1,661 Listeners

112,872 Listeners

56,544 Listeners

6,053 Listeners

9,947 Listeners

3 Listeners

12 Listeners